Oncology Institute (STLN) Stock Price, News & Analysis

Company Overview

The Oncology Institute, Inc. is a healthcare services company focused on providing specialized cancer care through community-based oncology practices. Its services generally include cancer diagnosis, treatment planning, chemotherapy and other infusion therapies, radiation referrals, supportive care, and ongoing monitoring for patients with cancer.

The company’s care model is designed to integrate oncologists, advanced practice providers, nurses, and other healthcare professionals while emphasizing coordinated and accessible treatment outside traditional hospital settings. It also works with health plans and other healthcare organizations to support value-based oncology care and improve the coordination and management of cancer treatment.

The Oncology Institute serves patients in the United States through its network of oncology providers and affiliated care locations. The company is commonly identified by the Nasdaq ticker symbol TOI; the symbol “STLN” may not correspond to The Oncology Institute.

Key Stats

• Today's Range: $6.21 to $6.41
• 50-Day Range: $5.91 to $7.05
• 52-Week Range: $2.32 to $7.13
• Volume: 359,116 shs
• Average Volume: 1.78 million shs
• Market Capitalization: $613.01 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.50
• Consensus Rating: Moderate Buy

Oncology Institute Stock Analysis - MarketRank™

Oncology Institute scored higher than 52% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Oncology Institute has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on no strong buy ratings, 4 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Oncology Institute has a consensus price target of $8.50, representing about 35.2% upside from its current price of $6.29.

Amount of Analyst Coverage

Oncology Institute has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.7 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Oncology Institute are expected to grow in the coming year, from ($0.21) to ($0.05) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Oncology Institute is -21.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.47% of the float of Oncology Institute has been sold short.

Short Interest Ratio / Days to Cover

Oncology Institute has a short interest ratio ("days to cover") of 7.35.

Change versus previous month

Short interest in Oncology Institute has recently increased by 3.48%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Oncology Institute does not currently pay a dividend.

Dividend Growth

Oncology Institute does not have a long track record of dividend growth.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: N/A

News Sentiment

Oncology Institute has a news sentiment score of 1.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Oncology Institute this week, compared to 2 articles on an average week.

Search Interest

Only 3 people have searched for STLN on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

4 people have added Oncology Institute to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days.

Company Ownership

• Score: 2.0 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Oncology Institute insiders have sold 645.16% more of their company's stock than they have bought. Specifically, they have bought $261,090.00 in company stock and sold $1,945,533.00 in company stock.

Percentage Held by Insiders

4.40% of the stock of Oncology Institute is held by insiders.

Percentage Held by Institutions

36.86% of the stock of Oncology Institute is held by institutions.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 10/08/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: N/A
• Industry: N/A
• Sub-Industry: N/A
• Current Symbol: NASDAQ:STLN
• Previous Symbol: NASDAQ:TOI
• CIK: 1799191
• Web: www.starlingoncology.com
• Phone: (562) 735-3226
• Fax: N/A
• Employees: 641
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Oncology Institute: $8.50
• High Price Target: $10.00
• Low Price Target: $7.00
• Potential Upside/Downside: +36.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.60
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.30)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$60.61 million
• Net Margins: -6.18%
• Pretax Margin: -6.18%
• Return on Equity: N/A
• Return on Assets: -21.51%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.36
• Quick Ratio: 1.15

Sales & Book Value

• Annual Sales: $502.73 million
• Price / Sales: 1.23
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.16) per share
• Price / Book: -38.97

Miscellaneous

• Outstanding Shares: 98,840,000
• Free Float: 94,490,000
• Market Cap: $616.27 million
• Optionable: N/A
• Beta: 0.39